• Silence Therapeutics Plc – New Conviction Buy stance

    March 11, 2017 | Posted by

    RNAi specialist with valuable embedded IP and prospective clinical trials positioned at the heart of an anticipated wave of consolidation within the sector Silence Therapeutics is an AIM listed biotechnology company focused on the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need. Described as being […]

  • Valeant – the end game is upon us

    March 7, 2017 | Posted by

    By Richard Jennings CFA Now is the optimum time for an industry player to make a bid Possible return of Takeda Pharma of Japan Levers likely to be pulled on crown jewel Bausch & Lomb Forward debt profile looks manageable Stock now trades at book value – almost unprecedented for pharma plays Sentiment has the […]